FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * Shameze Rampertab 2. Issuer Name and Ticker or Trading Symbol ASENSUS SURGICAL, INC. [ ASXC ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
EVP, Chief Financial Officer
(Last)          (First)          (Middle)
C/O ASENSUS SURGICAL, INC., 1 TW ALEXANDER DRIVE, SUITE 160		 3. Date of Earliest Transaction (MM/DD/YYYY)
2/3/2023
(Street)
DURHAM, NC 27703
(City)        (State)        (Zip)
 4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
 6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  2/4/2023    M    248512  A $0.00  342170  D   
Common Stock  2/4/2023    F(1)    103998  D $0.75  238172  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options  $0.75  2/3/2023    A     175000       (2) 2/3/2030  Common Stock  175000  $0.00  175000  D   
Restricted Stock Units (3) $0.00  2/3/2023    A     175000       (4)  (4) Common Stock  175000  $0.00  175000  D   
Restricted Stock Units (5) $0.00  2/3/2023    A     350000       (6)  (6) Common Stock  350000  $0.00  350000  D   
Restricted Stock Units (3) $0.00  2/4/2023    M        84270    (7)  (7) Common Stock  84270  $0.00  0  D   
Restricted Stock Units (3) $0.00  2/4/2023    M        19704    (8)  (8) Common Stock  19704  $0.00  19704  D   
Restricted Stock Units (5) $0.00  2/4/2023    M        19704    (9)  (9) Common Stock  19704  $0.00  19704  D   
Restricted Stock Units (3) $0.00  2/4/2023    M        62417    (10)  (10) Common Stock  62417  $0.00  124833  D   
Restricted Stock Units (5) $0.00  2/4/2023    M        62417    (11)  (11) Common Stock  62417  $0.00  124833  D   

Explanation of Responses:
(1)  This transaction represents the payment of a tax liability on the lapse of forfeiture restrictions on a derivative security and acquisition of the underlying shares.
(2)  Vests one-third annually on each of February 3, 2024, 2025 and 2026, subject to acceleration as set forth in the Registrant's Amended and Restated Incentive Compensation Plan ("Plan") and the Reporting Person's Employment Agreement with the Registrant ("Employment Agreement").
(3)  Each restricted stock unit ("RSU") represents the right to receive one share of the Registrant's common stock.
(4)  Forfeiture restrictions will lapse on the RSUs in three equal installments on each of February 4, 2024, 2025 and 2026, as long as the Reporting Person remains in continuous service during the vesting period, subject to acceleration as set forth in the Plan and the Employment Agreement.
(5)  Each performance-based restricted stock unit ("PRSU") represents the right to receive one share of the Registrant's common stock.
(6)  PRSU award with time-based vesting in three equal installments on each of February 4, 2024, 2025 and 2026, and performance-based vesting only if designated corporate goals are met.
(7)  Lapse of forfeiture restrictions on discretionary bonus RSUs.
(8)  Lapse of forfeiture on second one-third of an award of RSUs from this grant made on February 8, 2021. Forfeiture restrictions will lapse on the remaining RSUs on February 4, 2024, as long as the Reporting Person remains in continuous service during the vesting period, subject to acceleration as set forth in the Registrant's Plan and the Reporting Person's Employment Agreement.
(9)  Lapse of forfeiture restrictions on second one-third of a PRSU award granted on February 8, 2021, upon the achievement of time and performance goals. Forfeiture restrictions will lapse on the remaining PRSUs on February 4, 2024, as long as the Reporting Person provides continuous service during the vesting period, subject to acceleration as set forth in the Registrant's Plan and the Reporting Person's Employment Agreement.
(10)  Lapse of forfeiture restrictions on one-third of a RSU award granted on February 4, 2022. Forfeiture restrictions will lapse on the remaining RSUs on February 4, 2024 and 2025, as long as the Reporting Person provides continuous service to the Company during the vesting period and subject to acceleration as set forth in the Registrant's Plan and the Reporting Person's Employment Agreement.
(11)  Lapse of forfeiture restrictions on one-third of a PRSU award granted on February 4, 2022 upon the achievement of time and performance goals. Forfeiture restrictions will lapse on the remaining PRSUs on each of February 4, 2024 and 2025, subject to acceleration as set forth in the Registrant's Plan and the Reporting Person's Employment Agreement.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Shameze Rampertab
C/O ASENSUS SURGICAL, INC.
1 TW ALEXANDER DRIVE, SUITE 160
DURHAM, NC 27703

EVP, Chief Financial Officer

Signatures
/s/ Joshua Weingard, as attorney-in-fact for Shameze Rampertab 2/7/2023
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Asensus Surgical (AMEX:ASXC)
Graphique Historique de l'Action
De Fév 2023 à Mar 2023 Plus de graphiques de la Bourse Asensus Surgical
Asensus Surgical (AMEX:ASXC)
Graphique Historique de l'Action
De Mar 2022 à Mar 2023 Plus de graphiques de la Bourse Asensus Surgical